Certis Oncology Unveils Oncology Intelligence® Platform Integrating Predictive and Agentic AI with Biological Validation
Certis Oncology Unveils Oncology Intelligence® Platform Integrating Predictive and Agentic AI with Biological Validation
A Continuous Learning System for Oncology: By connecting prediction, exploration, and validation, Certis Oncology Intelligence creates a closed-loop system: This approach enables translational teams to move beyond static datasets and fragmented workflows, transforming both historical and newly generated data into a continuously evolving body of knowledge.
SAN DIEGO--(BUSINESS WIRE)--Certis Oncology, an AI-enabled translational science company, today announced the launch of Certis Oncology Intelligence®, an integrated platform designed to generate data-driven insights into therapeutic response by combining predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models.
Certis Oncology Intelligence® represents a new approach to translational research—one that connects computational prediction with real-world biological evidence in a continuous learning system.
Share
Certis Oncology Intelligence represents a new approach to translational research—one that connects computational prediction with real-world biological evidence in a continuous learning system.
“One of the central challenges in oncology drug development is that we generate enormous amounts of data, but struggle to translate that into reliable predictions of therapeutic response,” said Peter Ellman, Certis President and CEO. “Certis Oncology Intelligence was built to close that gap—linking prediction, biological context, and experimental validation into a system that continuously learns and improves over time.”
A Three-Layer Translational Intelligence System
Certis Oncology Intelligence is a secure, multi-tenant, closed loop system that integrates three data layers:
1. |
Predictive Intelligence Layer— CertisAI™ |
|
A patented, generalized drug-response foundation model trained to internalize relationships between chemical structure, tumor biology, and therapeutic response, CertisAI™ enables zero-shot prediction of how cancers are likely to respond to therapeutic agents, including novel compounds, even in the absence of prior experimental data. |
|
This predictive layer can be fine-tuned using sponsor training data, producing powerful, custom computational models uniquely aware of each company’s novel chemical space. |
2. |
Exploration Layer — Agentic Biospecimen Management |
|
Agentic biospecimen management enables researchers to dynamically query and analyze biological specimens together with their associated molecular and experimental datasets—offering a secure in silico environment in which to rapidly test hypotheses. |
|
Within the Oncology Intelligence platform, licensors can integrate their own proprietary datasets—molecular profiles, drug-response screening results, target binding data, and other translational information accumulated across programs over many years. |
|
By cross-referencing a company’s proprietary datasets with the platform’s foundational training data, the system can surface previously hidden relationships within each sponsor’s institutional knowledge base—generating new hypotheses, translational insights, and opportunities to advance or reprioritize therapeutic programs. |
3. |
Validation Layer—Functional Biological Evidence |
|
A key differentiator of this platform is its ability to learn from continuous biological validation using experimental data generated either by Certis or by its collaborators. Validation data may include results from studies performed in human-concordant cancer models such as patient-derived xenografts (PDX), as well as in vitro assays, organoid models, or clinical trials. |
|
Importantly, results from experimental studies are seamlessly fed back into the system as additional training data, continually improving predictive performance over time. |
Unlocking the Value of Translational Data
The platform is designed to help pharmaceutical and biotechnology companies:
- Integrate diverse datasets across programs and time
- Identify biologically meaningful drivers of therapeutic response
- Generate and test hypotheses more efficiently
- Improve confidence in translational and clinical decision-making
By enabling organizations to extract new insights from existing data while continuously generating new evidence, Certis Oncology Intelligence offers a scalable foundation for more predictive and data-driven oncology development.
Availability
Certis Oncology Intelligence is available to pharmaceutical and biotechnology partners through licensing and collaborative engagements.
About Certis Oncology
Certis Oncology is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology. By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.
Founded in 2016, Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in San Diego’s Sorrento Valley life sciences hub.
Contacts
Media Contact
Kristein King, Chief Marketing Officer
kking@certisoncology.com
858-952-1820
